APOE genotype-dependent differences in human astrocytic energy metabolism
Preprint
Abstract
The main genetic risk factor for Alzheimer’s disease (AD) is the presence of the apolipoprotein E4 ( APOE4 ) allele. While APOE4 increases the risk of developing AD, the APOE2 allele is protective and APOE3 is risk-neutral. In the brain, APOE is primarily expressed by astrocytes and plays a key role in various processes including cholesterol and lipid transport, neuronal growth, synaptic plasticity, immune response and energy metabolism. Disruptions in brain energy metabolism are considered a major contributor to AD pathophysiology, raising a key question about how different APOE isoforms affect the energy metabolism of human astrocytes. In this study, we generated astrocytes (iAstrocytes) from APOE -isogenic human induced pluripotent stem cells (iPSCs), expressing either APOE2, APOE3, APOE4 or carrying an APOE knockout ( APOE-KO ), and investigated APOE genotype-dependent changes in energy metabolism. ATP Seahorse assay revealed a reduced mitochondrial and glycolytic ATP production in APOE4 iAstrocytes. In contrast, proteomic GO enrichment analysis and mitochondrial stress tests indicated increased mitochondrial respiration and activity in APOE4 iAstrocytes, accompanied with elevated proton leak, while mitochondrial fusion and fission protein levels remain unchanged. Glycolysis stress tests also demonstrated enhanced glycolysis and glycolytic capacity in APOE4 iAstrocytes while genetically encoded nanosensor-based FLIM analysis revealed that APOE does not affect lactate dynamics. Mass spectrometry-based metabolomic analysis identified various energy and glucose metabolism-related pathways that were differentially regulated in APOE4 compared to the other genotypes, including mitochondrial electron transport chain and glycolysis. In general, APOE2 and APOE-KO iAstrocytes showed a very similar phenotype in all functional assays and differences between APOE2 / APOE-KO and APOE4 were stronger than between APOE3 and APOE4 . Our study provides evidence for APOE genotype-dependent effects on astrocyte energy metabolism and highlights alterations in the bioenergetic processes of the brain as important pathomechanisms in AD.Keywords
All Related Versions
- Published version: Frontiers in Cellular Neuroscience, 19, 1603657.
This publication has 43 references indexed in Scilit:
- Targeting VDAC: A potential therapeutic approach for mitochondrial dysfunction in Alzheimer's diseaseBrain Research, 2024
- APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population AncestryJAMA Neurology, 2023
- ApoE4-dependent lysosomal cholesterol accumulation impairs mitochondrial homeostasis and oxidative phosphorylation in human astrocytesCell Reports, 2023
- Exploring the therapeutic potential of mitochondrial uncouplers in cancerMolecular Metabolism, 2021
- APOE alters glucose flux through central carbon pathways in astrocytesNeurobiology of Disease, 2020
- Mitochondrial uncoupling, ROS generation and cardioprotectionBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2018
- VDAC Regulation: A Mitochondrial Target to Stop Cell Proliferation2018
- Evidence for brain glucose dysregulation in Alzheimer's diseaseAlzheimer's & Dementia, 2017
- Disrupted neural activity patterns to novelty and effort in young adult APOE‐e4 carriers performing a subsequent memory taskBrain and Behavior, 2017
- Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer DiseaseJAMA, 1997